Advanced Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major advanced renal cell carcinoma markets are expected to exhibit a CAGR of 4.53% during 2024-2034.
The advanced renal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Advanced Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Advanced renal cell carcinoma is a type of cancer that originates in the cells of the kidney's tubules, which are responsible for filtering waste materials and producing urine. In this condition, the tumors metastasize or spread from the kidney to various other organs or distant sites in the body, such as the lungs, liver, bones, lymph nodes, etc. The common indications of the ailment may include blood in the urine, pain or discomfort in the back or side, lack of appetite, swelling in the legs or ankles, a lump in the abdomen, weight loss, fatigue, general malaise, etc. However, in some cases, the disease may be asymptomatic until it reaches the last stage. The diagnosis of advanced renal cell carcinoma typically involves a combination of medical history review, characteristic findings, and physical examination. Several imaging tests, such as MRI and CT scans, are also recommended to identify tumors as well as evaluate the extent of metastasis. The healthcare provider may further perform a tissue biopsy to determine the specific subtype of the cancer.
The increasing cases of genetic conditions that can disrupt normal cell growth and division, resulting in the development and progression of tumors, are primarily driving the advanced renal cell carcinoma market. In addition to this, the rising prevalence of chronic high blood pressure, which may lead to changes in blood vessels, causing kidney damage and dysfunction, is also creating a positive outlook for the market. Moreover, the widespread adoption of tyrosine kinase inhibitors, such as sunitinib, pazopanib, lenvatinib, etc., for the treatment of the ailment as they can control and inhibit the metastasizing of cancerous cells in patients is further bolstering the market growth. Apart from this, the inflating demand for surgical interventions, including nephrectomy and metastasectomy, to reduce the tumor burden and improve response to other treatments is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-dose interleukin-2 therapy, which helps to enhance the body's natural defenses against cancerous cells by stimulating the immune system, is expected to drive the advanced renal cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the advanced renal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced renal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced renal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the advanced renal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the advanced renal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current advanced renal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the advanced renal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the advanced renal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the advanced renal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with advanced renal cell carcinoma across the seven major markets?
What is the size of the advanced renal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of advanced renal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Advanced Renal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for advanced renal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced renal cell carcinoma market?
What are the key regulatory events related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the advanced renal cell carcinoma market?
The advanced renal cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Advanced Renal Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Advanced renal cell carcinoma is a type of cancer that originates in the cells of the kidney's tubules, which are responsible for filtering waste materials and producing urine. In this condition, the tumors metastasize or spread from the kidney to various other organs or distant sites in the body, such as the lungs, liver, bones, lymph nodes, etc. The common indications of the ailment may include blood in the urine, pain or discomfort in the back or side, lack of appetite, swelling in the legs or ankles, a lump in the abdomen, weight loss, fatigue, general malaise, etc. However, in some cases, the disease may be asymptomatic until it reaches the last stage. The diagnosis of advanced renal cell carcinoma typically involves a combination of medical history review, characteristic findings, and physical examination. Several imaging tests, such as MRI and CT scans, are also recommended to identify tumors as well as evaluate the extent of metastasis. The healthcare provider may further perform a tissue biopsy to determine the specific subtype of the cancer.
The increasing cases of genetic conditions that can disrupt normal cell growth and division, resulting in the development and progression of tumors, are primarily driving the advanced renal cell carcinoma market. In addition to this, the rising prevalence of chronic high blood pressure, which may lead to changes in blood vessels, causing kidney damage and dysfunction, is also creating a positive outlook for the market. Moreover, the widespread adoption of tyrosine kinase inhibitors, such as sunitinib, pazopanib, lenvatinib, etc., for the treatment of the ailment as they can control and inhibit the metastasizing of cancerous cells in patients is further bolstering the market growth. Apart from this, the inflating demand for surgical interventions, including nephrectomy and metastasectomy, to reduce the tumor burden and improve response to other treatments is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-dose interleukin-2 therapy, which helps to enhance the body's natural defenses against cancerous cells by stimulating the immune system, is expected to drive the advanced renal cell carcinoma market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the advanced renal cell carcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for advanced renal cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the advanced renal cell carcinoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the advanced renal cell carcinoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the advanced renal cell carcinoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current advanced renal cell carcinoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the advanced renal cell carcinoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the advanced renal cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the advanced renal cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of advanced renal cell carcinoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with advanced renal cell carcinoma across the seven major markets?
What is the size of the advanced renal cell carcinoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of advanced renal cell carcinoma?
What will be the growth rate of patients across the seven major markets?
Advanced Renal Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for advanced renal cell carcinoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the advanced renal cell carcinoma market?
What are the key regulatory events related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by status related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by phase related to the advanced renal cell carcinoma market?
What is the structure of clinical trial landscape by route of administration related to the advanced renal cell carcinoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADVANCED RENAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADVANCED RENAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADVANCED RENAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADVANCED RENAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADVANCED RENAL CELL CARCINOMA - UNMET NEEDS
10 ADVANCED RENAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 ADVANCED RENAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Advanced Renal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Fotivda (Tivozanib) - AVEO Oncology/Kyowa Kirin
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Proleukin (Aldesleukin) - Clinigen/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sutent (Sunitinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Inlyta (Axitinib) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ADVANCED RENAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Advanced Renal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 MEDI5752 - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NKT 2152 - NiKang Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ADVANCED RENAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADVANCED RENAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADVANCED RENAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Advanced Renal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Advanced Renal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Advanced Renal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Advanced Renal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Advanced Renal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Advanced Renal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Advanced Renal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Advanced Renal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
16 ADVANCED RENAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADVANCED RENAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADVANCED RENAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ADVANCED RENAL CELL CARCINOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ADVANCED RENAL CELL CARCINOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ADVANCED RENAL CELL CARCINOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 ADVANCED RENAL CELL CARCINOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ADVANCED RENAL CELL CARCINOMA - UNMET NEEDS
10 ADVANCED RENAL CELL CARCINOMA - KEY ENDPOINTS OF TREATMENT
11 ADVANCED RENAL CELL CARCINOMA - MARKETED PRODUCTS
11.1 List of Advanced Renal Cell Carcinoma Marketed Drugs Across the Top 7 Markets
11.1.1 Fotivda (Tivozanib) - AVEO Oncology/Kyowa Kirin
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Proleukin (Aldesleukin) - Clinigen/Novartis
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Sutent (Sunitinib) - Pfizer
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Inlyta (Axitinib) - Pfizer
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Lenvima (Lenvatinib) - Eisai Co Ltd/Merck & Co
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 ADVANCED RENAL CELL CARCINOMA - PIPELINE DRUGS
12.1 List of Advanced Renal Cell Carcinoma Pipeline Drugs Across the Top 7 Markets
12.1.1 MEDI5752 - AstraZeneca
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NKT 2152 - NiKang Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. ADVANCED RENAL CELL CARCINOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ADVANCED RENAL CELL CARCINOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ADVANCED RENAL CELL CARCINOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Advanced Renal Cell Carcinoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Advanced Renal Cell Carcinoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Advanced Renal Cell Carcinoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Advanced Renal Cell Carcinoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Advanced Renal Cell Carcinoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Advanced Renal Cell Carcinoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Advanced Renal Cell Carcinoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Advanced Renal Cell Carcinoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Advanced Renal Cell Carcinoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Advanced Renal Cell Carcinoma - Access and Reimbursement Overview
16 ADVANCED RENAL CELL CARCINOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ADVANCED RENAL CELL CARCINOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ADVANCED RENAL CELL CARCINOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
